Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials

Guang-Zhi Ning1,2, Shun-Li Kan2, Ling-Xiao Chen2, Lei Shangguan1, Shi-Qing Feng2 & Yue Zhou3

Venous thromboembolism (VTE) is the most widespread severe complication after total hip arthroplasty (THA) and total knee arthroplasty (TKA). We conducted this meta-analysis to further validate the benefits and harms of rivaroxaban use for thromboprophylaxis after THA or TKA. We thoroughly searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. Trial sequential analysis (TSA) was applied to test the robustness of our findings and to obtain a more conservative estimation. Of 316 articles screened, nine studies were included. Compared with enoxaparin, rivaroxaban significantly reduced symptomatic VTE ($P = 0.0001$) and symptomatic deep vein thrombosis (DVT; $P = 0.0001$) but not symptomatic pulmonary embolism ($P = 0.57$). Furthermore, rivaroxaban was not associated with an increase in all-cause mortality, clinically relevant non-major bleeding and postoperative wound infection. However, the findings were accompanied by an increase in major bleeding ($P = 0.02$). The TSA demonstrated that the cumulative z-curve crossed the traditional boundary but not the trial sequential monitoring boundary and did not reach the required information size for major bleeding. Rivaroxaban was more beneficial than enoxaparin for preventing symptomatic DVT but increased the risk of major bleeding. According to the TSA results, more evidence is needed to verify the risk of major bleeding with rivaroxaban.

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is the most widespread severe complication after total hip arthroplasty (THA) and total knee arthroplasty (TKA)1–3. Without thromboprophylaxis, the incidence of symptomatic DVT ranges from 15–30%, and the risk of symptomatic PE occurs in 0.5–2% of patients undergoing THA or TKA4–7. VTE results in the mortality of more than half a million people in Europe every year8.

Low molecular weight heparin (enoxaparin), synthetic pentasaccharides (fondaparinux), or vitamin K antagonists (warfarin) are recommended and used for routine postoperative thromboprophylaxis9–11. However, the need for daily subcutaneous injections, ongoing dose adjustments and laboratory monitoring have complicated their use12,13.

The drawbacks of existing anticoagulants have driven the development of new oral anticoagulants: oral direct factor Xa inhibitors. Rivaroxaban is one of the first licensed novel oral direct factor Xa inhibitors. The National Institute of Clinical Excellence (NICE) and the American College of Chest Physicians (ACCP) have approved the use of rivaroxaban for thromboprophylaxis following THA and TKA11,15.

1Department of Orthopaedics, Xinqiao Hospital, Third Military Medical University, Xinqiao Road, Shapingba District, Chongqing 400037, China. 2Department of Orthopaedics, Tianjin Medical University General Hospital, 154 Anshan Road, Heping District, Tianjin 300052, China. Correspondence and requests for materials should be addressed to S.Q.F. (email: sqfeng@tmu.edu.cn) or Y.Z. (email: zhoyue2015xinqiao@163.com)
Several studies have assessed the benefits and harms of rivaroxaban for patients following THA or TKA. One study found that rivaroxaban was associated with a greater risk of major bleeding compared with enoxaparin. Some systematic reviews have demonstrated that there was no difference in the incidence of major bleeding between rivaroxaban and enoxaparin and that rivaroxaban was more beneficial than enoxaparin for decreasing the risk of VTE. However, most of those reviews included only favorable rivaroxaban dosage or studies that reported phase III trials. For these reasons, we conducted this systematic review and meta-analysis to further explicate the benefits and harms of rivaroxaban for thromboprophylaxis after THA or TKA. Furthermore, we applied trial sequential analysis (TSA) to test the robustness of our findings and to obtain a more conservative estimation.

Results
Study search. Figure 1 presents a summary of the study selection process. Of 316 articles screened, 301 were excluded because they were duplicates or did not meet the eligibility criteria. After verifying the full text of the remaining 15 articles, we discarded six studies. Finally, a total of nine studies met the eligibility criteria and were included in the quantitative analysis.

Study characteristics. The study characteristics of the included studies are presented in Table 1. A total of nine randomized controlled trials were identified, of which seven used the enoxaparin regimen that is approved in Europe and two utilized the enoxaparin regimen approved in North America. Of the included studies, four used multiple dosages of rivaroxaban; a single dosage of rivaroxaban was used in the remaining five trials. The nine trials included 15,829 participants. Five of the trials compared rivaroxaban with enoxaparin for THA treatment; four trials compared the two treatments in TKA patients. Within these trials, 8781 participants were randomized to the rivaroxaban treatment, and 7048 patients were randomized to the enoxaparin treatment. All of the articles were reported in English between 2005 and 2014. The duration of follow-up ranged from 28 to 75 days. The mean age of the patients ranged between 62 and 68 years. There was a high proportion of females, ranging from 53–76%.
Table 1. Baseline characteristics of studies included in the meta-analysis.

| Source      | Type of surgery | Type of intervention (dose, timing of first dose after surgery) | Experimental group | Control group | Type of surgery duration (minutes) | Use of neoraxial anaesthesia (%) | No. of patients | Mean age (years), female (%) | Mean weight (kg) | Day of venography | Follow up (days) |
|-------------|-----------------|---------------------------------------------------------------|-------------------|---------------|-----------------------------------|----------------------------------|----------------|-------------------------------|-----------------|----------------|-----------------|
| Eriksson 2006a | THA             | Rivaroxaban 2.5, 5, 10, 20, or 30 mg twice daily, 5–9 days (6–8 hours) | 10 mg once daily, 5–9 days (about 12 hours*) | Enoxaparin 40 mg | THA 82                            | 70                               | 722            | 65, 59, 77                     | 5–9             | 38–68          |
| Eriksson 2006b | TKA             | Rivaroxaban 10, 20, or 30 mg once daily, 5–9 days (6–8 hours) | 10 mg once daily, 5–9 days (about 12 hours*) | Enoxaparin 40 mg | THA 84                            | 62                               | 873            | 66, 64, 75                     | 6–10            | 35–69          |
| Eriksson 2007  | TKA             | Rivaroxaban 2.5, 5, 10, 20, or 30 mg twice daily, rivaroxaban 30 mg once daily, 5–9 days (6–8 hours) | 20 mg twice daily, 5–9 days (6–8 hours) | Enoxaparin 40 mg | THA NA                            | 73                               | 641            | 64, 54, 79                     | 5–9             | 38–68          |
| Eriksson 2008  | TKA             | Rivaroxaban 10 mg once daily, 35d (6–8 hours) | 10 mg once daily, 35 days (about 12 hours*) | Enoxaparin 40 mg | THA 91                            | 70                               | 4541           | 63, 56, 78                     | 36              | 66–71          |
| Kakkar 2008    | TKA             | Rivaroxaban 10 mg once daily, 31–39 days (6–8 hours) | 10 mg once daily, 31 days (about 12 hours*) | Enoxaparin 40 mg | THA 93                            | 71                               | 2509           | 62, 53, 75                     | 32–40           | 62–75          |
| Lassen 2008    | TKA             | Rivaroxaban 10 mg once daily, 10–14 days (6–8 hours) | 10 mg once daily, 10–14 days (about 12 hours*) | Enoxaparin 40 mg | TKA 97                            | 79                               | 2531           | 68, 67, 81                     | 11–15           | 41–50          |
| Turpie 2005    | TKA             | Rivaroxaban 2.5, 5, 10, 20, or 30 mg twice daily, 5–9 days (6–8 hours) | 20 mg twice daily, 5–9 days (12–24 hours) | Enoxaparin 30 mg | TKA 91                            | 53                               | 621            | 66, 55, 89                     | 5–9             | 37–67          |
| Turpie 2009    | TKA             | Rivaroxaban 10 mg once daily, 10–14 days (6–8 hours) | 10 mg twice daily, 10–14 days (12–24 hours) | Enoxaparin 30 mg | TKA 100                           | 81                               | 3148           | 65, 64, 84                     | 11–15           | 40–49          |
| Zou 2014       | TKA             | Rivaroxaban 10 mg once daily, 10–14 days (12 hours) | 10 mg once daily, 10–14 days (12 hours) | Enoxaparin 40 mg | TKA 85                            | 100%                             | 214            | 65, 76, NA                     | 8–14†, 22–28†   | 28             |

The major bleeding rates described in the four RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes) trials with rivaroxaban were 7–8 times lower than those of the enoxaparin groups in the remaining studies. The RECORD trials’ definition of major bleeding that excluded most bleeding from wounds, which differed from the definition of previous studies, resulted in this phenomenon. This matter initially barred us from incorporating data on major bleeding into our report. However, an FDA review described the major bleeding rates of the RECORD trials without eliminating major wound bleedings. Therefore, the major bleeding data of the RECORD trials, as reported by the FDA, was utilized in this study.

**Risk of bias in the included studies.** One study had an unclear risk of bias. Eight studies had an unclear risk of bias. The high risk of bias was based on the use of the open-label method. Random sequence generation was carried out adequately in all the studies. Allocation concealment was adequate in eight studies. Seven studies blinded the participants, personnel, and outcome assessors adequately. Seven trials were sponsored by a pharmaceutical company. The details about the risk of bias for each study are presented in Fig. 2.

**Quality of evidence assessment.** Details regarding the Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence profiles for the outcomes are presented in Table 2. The GRADE level of evidence was low for symptomatic venous thromboembolism, major bleeding, and clinically relevant non-major bleeding; and moderate for all-cause mortality, symptomatic deep vein thrombosis, symptomatic pulmonary embolism, and postoperative wound infection.

**Primary outcomes**

**Major bleeding.** Eight randomized controlled trials randomized 15,615 participants and compared rivaroxaban with enoxaparin. Rivaroxaban was associated with a significant increase in the risk of major bleeding (relative risk (RR) = 1.37, 95% CI 1.05 to 1.78, P = 0.02; I² = 0%; Fig. 3a) compared with enoxaparin. The cumulative z-curve crossed the traditional boundary but not the trial sequential monitoring boundary and did not reach the required information size, suggesting the need for more evidence to establish whether rivaroxaban is associated with greater harm compared with enoxaparin (Fig. 4).
Symptomatic venous thromboembolism. Nine studies including 15,829 participants reported data on symptomatic venous thromboembolism. Compared with enoxaparin, rivaroxaban significantly decreased symptomatic venous thromboembolism (RR = 0.44, 95% confidence interval (CI) 0.29 to 0.67, P = 0.0001; I² = 0%; Fig. 3b). TSA demonstrated that the required information size had been reached and the cumulative z-curve crossed the traditional boundary, indicating further studies were not needed and would be unlikely to change the inferences (Fig. 5).

Secondary Outcomes
Rivaroxaban reduced the incidence of symptomatic DVT (RR = 0.36, 95% CI 0.21 to 0.61, P = 0.0001; I² = 0%; Fig. 6a) but not the risk of symptomatic PE (RR = 0.79, 95% CI 0.35 to 1.79, P = 0.57; I² = 12%; Fig. 6b) compared with enoxaparin. Rivaroxaban was not different from enoxaparin in terms of the relative risk of all-cause mortality (RR = 0.63, 95% CI 0.27 to 1.44, P = 0.27), and there was no evidence of heterogeneity (see Supplementary Fig. S1). Similarly, neither rivaroxaban nor enoxaparin influenced the risk of clinically relevant non-major bleeding (RR = 1.23, 95% CI 1.00 to 1.51, P = 0.05; I² = 0%; see Supplementary Fig. S2) and postoperative wound infection (RR = 0.97, 95% CI 0.57 to 1.66, P = 0.92; I² = 0%; see Supplementary Fig. S3). The TSA for symptomatic DVT showed that the cumulative z-curve crossed the traditional boundary, and the required information size was reached, indicating that further studies were unlikely to change the inference (see Supplementary Fig. S4). The TSA for all-cause mortality and clinically relevant non-major bleeding showed that the cumulative z-curve did not cross the traditional boundary, suggesting that additional trials are needed to further verify the inferences.
| Quality assessment | No of patients | Effect |
|--------------------|----------------|--------|
| Symptomatic venous thromboembolism (follow-up 28–75 days) | 9 randomised trials | Serious¹ no serious inconsistency no serious indirectness Serious² None |
| | | Rivaroxaban Enoxaparin Relative (95% CI) Absolute Quality* Importance |
| | | 38/8781 (0.4%) 72/7048 (1%) RR 0.44 (0.29 to 0.67) 6 fewer per 1000 (from 3 fewer to 7 fewer) ⊗ ⊗ ⊗ ⊗ ⊗ ⊗ LOW CRITICAL |
| Major bleeding (follow-up 35–75 days) | 8 randomised trials | Serious¹ no serious inconsistency no serious indirectness Serious³ None |
| | | Rivaroxaban Enoxaparin Relative (95% CI) Absolute Quality* Importance |
| | | 185/8679 (2.1%) 92/6936 (1.3%) RR 1.37 (1.05 to 1.76) 5 more per 1000 (from 1 more to 10 more) ⊗ ⊗ ⊗ ⊗ ⊗ ⊗ LOW CRITICAL |
| All-cause mortality (follow-up 35–75 days) | 8 randomised trials | Serious¹ no serious inconsistency no serious indirectness No serious imprecision None |
| | | Rivaroxaban Enoxaparin Relative (95% CI) Absolute Quality* Importance |
| | | 10/8676 (0.1%) 15/6936 (0.2%) RR 0.63 (0.27 to 1.44) 1 fewer per 1000 (from 2 fewer to 1 more) ⊗ ⊗ ⊗ ⊗ ⊗ ⊗ CRITICAL |
| Symptomatic deep vein thrombosis (follow-up 28–75 days) | 9 randomised trials | Serious¹ no serious inconsistency no serious indirectness No serious imprecision None |
| | | Rivaroxaban Enoxaparin Relative (95% CI) Absolute Quality* Importance |
| | | 19/8781 (0.2%) 53/7048 (0.8%) RR 0.36 (0.21 to 0.61) 5 fewer per 1000 (from 3 fewer to 6 fewer) ⊗ ⊗ ⊗ ⊗ ⊗ ⊗ CRITICAL |
| Symptomatic pulmonary embolism (follow-up 28–75 days) | 9 randomised trials | Serious¹ no serious inconsistency no serious indirectness No serious imprecision None |
| | | Rivaroxaban Enoxaparin Relative (95% CI) Absolute Quality* Importance |
| | | 19/8781 (0.2%) 19/7048 (0.3%) RR 0.79 (0.35 to 1.79) 1 fewer per 1000 (from 2 fewer to 2 more) ⊗ ⊗ ⊗ ⊗ ⊗ ⊗ CRITICAL |
| Clinically relevant non-major bleeding (follow-up 35–75 days) | 8 randomised trials | Serious¹ no serious inconsistency no serious indirectness Serious⁴ None |
| | | Rivaroxaban Enoxaparin Relative (95% CI) Absolute Quality* Importance |
| | | 251/8679 (2.9%) 156/6936 (2.2%) RR 1.23 (1 to 1.51) 5 more per 1000 (from 0 more to 11 more) ⊗ ⊗ ⊗ ⊗ ⊗ ⊗ MODERATE CRITICAL |
| Postoperative wound infection (follow-up 40–75 days) | 4 randomised trials | Serious⁵ no serious inconsistency no serious indirectness No serious imprecision None |
| | | Rivaroxaban Enoxaparin Relative (95% CI) Absolute Quality* Importance |
| | | 27/6356 (0.4%) 28/6373 (0.4%) RR 0.97 (0.57 to 1.66) 0 fewer per 1000 (from 2 fewer to 3 more) ⊗ ⊗ ⊗ ⊗ ⊗ ⊗ CRITICAL |

Table 2. GRADE evidence profile. RR: relative risk. ¹All the trials were judged to be at high risk of bias or unclear risk of bias. ²RR with 95% CI for one trial was 3.06 (0.17–56.46). ³RR with 95% CI for one trial was 14.60 (0.89–239.70). ⁴RR with 95% CI for one trial was 9.12 (0.55–149.84). ⁵All the trials were judged to be at unclear risk of bias. GRADE Working Group grades of evidence: high quality = further research is very unlikely to change our confidence in the estimate of effect; moderate quality = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality = we are very uncertain about the estimate.
(see Supplementary Figs S5 and S6). Because too little information could be used, no TSA could be conducted for symptomatic PE and postoperative wound infection.

**Subgroup analyses, sensitivity analyses, meta-regression analyses and publication bias.**

Subgroup analyses based on type of surgery (THA or TKA), allocation concealment (adequate or unclear), number of patients (<1000 or ≥1000), rivaroxaban dosage (a single dosage or multiple dosages), enoxaparin dosage...
(30 mg twice daily or 40 mg once daily), and surgery duration (<90 minutes or ≥90 minutes) did not exhibit noteworthy differences (see Supplementary Table S1). The decrease in the risk of symptomatic venous thromboembolism was higher in studies with adequate allocation concealment, ≥1000 patients, a single rivaroxaban
Discussion

The present meta-analysis demonstrated that compared with enoxaparin, rivaroxaban significantly decreased the rate of symptomatic VTE in patients undergoing THA or TKA; additionally, it reduced the risk of symptomatic DVT but not symptomatic PE. The evidence of efficacy was verified by most subgroup analyses and the TSA. In addition, rivaroxaban was associated with a significant increase in major bleeding and a higher clinically relevant non-major bleeding tendency. There was no difference in all-cause mortality and postoperative wound infection.

This meta-analysis showed that rivaroxaban significantly increased the incidence of major bleeding, but not clinically relevant non-major bleeding, for patients with THA and TKA. Opina and colleagues confirmed that rivaroxaban was associated with a 1.99-times higher RR for major bleeding compared with enoxaparin, which was consistent with the findings of this analysis. However, Gómez-Outes et al. and Cao et al. observed that the incidence of major bleeding did not significantly increase with rivaroxaban compared with enoxaparin. The major bleeding results reported in the four phase II clinical trials suggest that major bleeding mainly occurred in the high-dose rivaroxaban groups. Hence, the reason for the differing results may be that some reviews only considered the 10 mg once daily dosage of rivaroxaban in the phase II clinical trials. Several studies have indicated that rivaroxaban was not associated with a significant increase in clinically relevant non-major bleeding.

Rivaroxaban appeared more efficient than enoxaparin in preventing symptomatic VTE and symptomatic DVT; however, there was no significant difference in the risk of symptomatic PE. This finding was consistent among numerous studies. The phase IV non-interventional study of rivaroxaban further verified that rivaroxaban significantly reduced the rate of symptomatic VTE. Because of the low incidence of symptomatic PE following THA and TKA, additional large trials may be needed to reveal any underlying advantage of rivaroxaban for this result. In a previous meta-analysis, Gómez-Outes and colleagues found that rivaroxaban was associated with a significant decrease in symptomatic VTE and symptomatic DVT, but not symptomatic PE. Although these results were consistent with ours, this study only selected the 10 mg once daily dosage of rivaroxaban in four phase II clinical trials, suggesting the possibility that the studies selected favorable results and presenting a possible loss of information. The current analysis included all of the rivaroxaban dosages used in the phase II clinical trials; consequently, our findings are more reliable than those of analyses that excluded some dosages. Moreover, we included another new clinical trial, which increased the statistical power. Furthermore, TSA was used in this meta-analysis to generate more conservative estimates. The TSA indicated that the present research provides ample and convincing evidence.

It has been confirmed that excessive anticoagulation may result in increased wound complications and postoperative infections. However, our analysis did not support this hypothesis. Our study observed that there was no significant difference between rivaroxaban and enoxaparin in terms of postoperative wound infection and all-cause mortality. Furthermore, previous analyses have confirmed our findings.

There are some highlights in this meta-analysis. The methodology recommended by the Cochrane Collaboration was applied. A thorough literature search of PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) was performed without language restriction. Furthermore, two investigators independently appraised the risk of bias of the individual studies and assessed the quality of evidence using the GRADE approach for helping clinicians make clinical decisions. In addition, we utilized TSA to test the robustness of our findings and obtain a more conservative estimation.

Our study has several limitations. First, the trials were not consistent in terms of the duration of intervention. A short duration of treatment may affect the benefits and harms of rivaroxaban. Second, only two trials investigated the enoxaparin regimen of 30 mg daily. The inadequate number of patients in these two trials could not demonstrate a significant difference. Additionally, it was challenging to incorporate numerous trials within the same drug development program. However, because of the large number of participants and the fact that we included only randomized controlled trials, we believe that this analysis is convincing. Furthermore, because of the limited number of eligible studies, we did not assess publication bias. Our results should be interpreted with the consideration of the underlying publication bias. Finally, all of the studies were sponsored by pharmaceutical companies. This may also influence the robustness of our conclusions.

In conclusion, rivaroxaban was more beneficial than enoxaparin for preventing symptomatic VTE and symptomatic DVT, but not symptomatic PE, after THA and TKA. Moreover, rivaroxaban was not associated with an increase in all-cause mortality, clinically relevant non-major bleeding or postoperative wound infection. However, rivaroxaban was associated with an increase in major bleeding. According to the TSA results, more evidence is needed to verify the incidence of major bleeding associated with rivaroxaban.

Methods

Search strategy and study selection. We performed a thorough literature search of PubMed, EMBASE, and CENTRAL to identify randomized controlled trials that compared rivaroxaban with enoxaparin for patients undergoing THA or TKA. The literature search was completed on September 19, 2015. We combined MeSH terms with text words in the electronic search. The search terms pertaining to THA and TKA were combined with terms related to both rivaroxaban and enoxaparin. The details of the search strategies are presented in Supplementary...
Eligibility criteria.  
(1) Participants: Only trials enrolling adult patients undergoing THA or TKA were included in this meta-analysis.

(2) Interventions: The intervention in the experimental group was, the new oral anticoagulant, rivaroxaban.

(3) Comparisons: The intervention in the control group was the approved treatment, enoxaparin 40 mg once daily (Europe) or 30 mg twice daily (North America).

(4) Outcomes: Studies were qualified when at least one of the following outcomes were described: symptomatic venous thromboembolism, major bleeding, all-cause mortality, clinically relevant non-major bleeding, and postoperative wound infection.

(5) Study design: Only randomized controlled trials were considered as qualified in the present study.

Data extraction and outcome measures.  For the included studies, two assessors independently carried out the data extraction. Study characteristics, including details regarding methodology, patients, experimental and control interventions, and outcomes were extracted. For the outcomes of interest, we extracted the number of events and the total sample sizes. If the data were not described in the text of the articles, we extracted data from the tables and diagrams, if available. The authors were contacted for extra information if sufficient information was not available from the text.

The primary outcome measures of interest were major bleeding and symptomatic VTE (symptomatic DVT or symptomatic PE). The secondary outcome measures consisted of all-cause mortality, symptomatic deep vein thrombosis, symptomatic pulmonary embolism, clinically relevant non-major bleeding, and postoperative wound infection.

Risk of bias assessment.  We used the risk of bias tool to evaluate all of the included studies in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). Two investigators individually assessed all of the studies. The assessed domains included random sequence generation, allocation concealment, blinding of participants and personnel, blinding of the result assessor, incomplete result data, selective reporting of outcomes, and other bias (baseline balance and fund). All of the domains were ranked as low risk of bias, high risk of bias, or unclear risk of bias. A trial was considered to have a high risk of bias if one or more key domains were considered to be at high risk. A trial was considered to have a low risk of bias if all key domains were considered to be at low risk. Otherwise, the studies were regarded as having an unclear risk of bias.

Quality of evidence assessment.  The quality of evidence for each pooled outcome was rated according to the GRADE system. During the assessment process, the evidence for each pooled analysis was rated according to five major criteria: risk of bias, inconsistency, indirectness, imprecision and publication bias. Each pooled analysis was defined as high, moderate, low, or very low quality. Two reviewers conducted the appraisals independently. Consensus was utilized to resolve any disagreement. GRADE Pro version 3.6 was used to generate summary tables.

Statistical analysis.  In this meta-analysis, RR and the corresponding 95% CI were calculated for all of the outcomes. The random-effect model was employed for the present meta-analysis. The I² statistic was used to assess the heterogeneity across studies. I² > 50% was determined to indicate significant heterogeneity. Based on the type of surgery (THA or TKA), allocation concealment (adequate or unclear), number of patients (≤1000 or >1000), rivaroxaban dosage (a single dosage or multiple dosages), enoxaparin dosage (30 mg twice daily or 40 mg once daily), and surgery duration (<90 minutes or ≥90 minutes), we conducted subgroup analyses for the primary outcomes. P < 0.05 indicated a statistically significant interaction between the estimates of the subgroups. We performed the sensitivity analyses using a fixed-effect model and odds ratio (OR) with both random-effect and fixed-effect models, and by removing trials one by one. Furthermore, we carried out a meta-regression analysis to evaluate the potential effect of mean age on the primary outcomes. We used Egger’s linear regression test and funnel plots to test the publication bias when more than ten publications were included. P values < 0.05 denoted statistically significant differences. We completed the statistical analyses using Review Manager version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, 2014) and Stata version 12.0 (Stata Corp, College Station, TX).
**Trial Sequential Analysis.** In a meta-analysis, the risk of false positive errors (type I error) may arise. This phenomenon may result from random errors when a small number of studies and participants is analyzed and repetitive statistical testing of the accumulation of additional data. To correct for the incremental risk of type I errors, we used TSA to identify whether the findings of the cumulative meta-analysis were dependable and conclusive. TSA combines the required information size with trial sequential monitoring boundaries which adjust the confidence intervals and decrease type I errors. When the cumulative z-curve crosses the trial sequential monitoring boundary or enters the futility area, an adequate level of evidence for the anticipated intervention effect may have been reached and no further trials are needed. If the z-curve does not cross any of the boundaries and the required information size has not been reached, the evidence is inadequate to reach a conclusion.

We estimated a diversity-adjusted information size in accordance with the diversity of the intervention effect estimates among the included studies. The TSA was conducted to maintain a type I error of 5% with a power of 80%. In the present meta-analysis, we calculated the required information size using the estimates of the intervention effects of trials with adequate allocation concealment. Trial sequential analysis software version 0.9 beta (www.ctu.dk/tsa) was used for these analyses.

**References**

1. Haas, S. B., Barrack, R. L., Westrich, G. & Lachiewicz, P. F. Venous thromboembolic disease after total hip and knee arthroplasty. *The Journal of bone and joint surgery. American volume* 90, 2764–2780 (2008).
2. Phillips, C. B. et al. Incidence rates of dislocation, pulmonary embolism, and deep infection during the first six months after elective total hip replacement. *The Journal of bone and joint surgery. American volume* 85-a, 20–26 (2003).
3. Zhan, C., Kaczmarek, R., Loyo-Berrios, N., Sangl, J. & Bright, R. A. Incidence and short-term outcomes of primary and revision hip replacement in the United States. *The Journal of bone and joint surgery. American volume* 89, 526–533, doi: 10.2106/jbjs.l.00952 (2007).
4. Huo, M. H. et al. Post-discharge venous thromboembolism and bleeding in a large cohort of patients undergoing total hip or total knee arthroplasty. *Journal of Clinical Outcomes Management* 19, 355–363 (2012).
5. Januel, J. M. et al. Symptomatic in-hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis: a systematic review. *Jama* 307, 294–303, doi: 10.1001/jama.2011.2029 (2012).
6. Xing, K. H. et al. Has the incidence of deep vein thrombosis in patients undergoing total hip/knee arthroplasty changed over time? A systematic review of randomized controlled trials. *Thromb Res* 123, 24–34, doi: 10.1016/j.thromres.2008.05.005 (2008).
7. Nicolaides, A. N. et al. Prevention and treatment of venous thromboembolism–International Consensus Statement. *International angiology: a journal of the International Union of Angiology* 32, 111–260 (2013).
8. Cohen, A. T. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. *Thrombosis and haemostasis* 98, 756–764 (2007).
9. Geerts, W. H. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 133, 381s–453s, doi: 10.1378/chest.08-0656 (2008).
10. Johanson, N. A. et al. Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. *The Journal of the American Academy of Orthopaedic Surgeons* 17, 183–196 (2009).
11. Lieberman, J. R. & Pensak, M. J. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. *The Journal of bone and joint surgery. American volume* 95, 1801–1811, doi: 10.2106/jbjs.l.01328 (2013).
12. Hirsh, J. & Raschke, R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest* 126, 188s–203s, doi: 10.1378/chest.126.3_supp1.188S (2004).
13. Hirsh, J. Oral anticoagulant drugs. *The New England journal of medicine* 324, 1865–1875, doi: 10.1056/nejm199010273242606 (1991).
14. Bates, S. M. & Weitz, J. I. The status of new anticoagulants. *Br J Haematol* 134, 3–19, doi: 10.1111/j.1365-2141.2006.06134.x (2006).
15. Atkins, R. M. NICE and venous thromboembolism. *The New England journal of medicine* 372, 31–39, doi: 10.1056/nejm200602093720301 (2006).
16. Kweekel, F., Sinsky, M., van der Heijden, F., Hartog, R. & Stijnen, T. The status of new oral anticoagulants for the prevention of venous thromboembolism in patients undergoing knee or hip replacement: a systematic review and meta-analysis. *European Journal of Pharmaceutical Sciences* 35, 90–99, doi: 10.1016/j.ejps.2008.11.004 (2009).
17. Gómez-Outes, A., Terleira-Fernández, A. I., Suárez-Gea, M. L. & Vargas-Castrillón, E. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip replacement. *Journal of Bone and Joint Surgery - Series B* 50, 636–644, doi: 10.1302/0301-620x.92b5.24869 (2010).
18. Alves, C., Batel-Marques, F. & Macêdo, A. F. Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis. *European Journal of Pharmacology and Therapeutics* 17, 266–276 (2012).
19. Russell, R. D. & Huo, M. H. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty. *Journal of Arthroplasty* 28, 1477–1481 (2013).
20. Cao, Y. B., Zhang Jd Fau - Shen, H., Shen H Fau - Jiang, Y. Y. & Jiang, Y. Y. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. *Thrombosis Research* 127, 625–634 (2011).
21. Eriksson, B. I. et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. *Thrombosis Research* 127, 525–534 (2011).
22. Pouloos, N., Sukomboon, N., Wattanason, K., Kosumwisaaksakul, B. & Chaopanont, P. Meta-analysis of the efficacy and safety of rivaroxaban for treatment of acute symptomatic deep vein thrombosis. *European Journal of Pharmaceutical Sciences* 50 (2013).
23. Alves, C., Batel-Marques, F. & Macêdo, A. F. Apixaban and rivaroxaban safety after hip and knee arthroplasty: A meta-analysis. *Journal of Cardiovascular Pharmacology and Therapeutics* 17, 266–276 (2012).
24. Kwong, L. & Turpie, A. G. Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients. *Curr Orthop Pract* 26, 299–305, doi: 10.1097/bco.0000000000000232 (2015).
25. Eriksson, B. I. et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. *Journal of Thrombosis and Haemostasis* 121, 128–129 (2006).
26. Eriksson, B. I. et al. Dose-escalation study of rivaroxaban (BAY 59-7939) - an oral, direct Factor Xa inhibitor - for the prevention of venous thromboembolism in patients undergoing total hip replacement. *Thrombosis Research* 120, 685–693 (2007).
27. Eriksson, B. I. et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. *Circulation* 114, 2374–2381 (2006).
28. Eriksson, B. I. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *New England Journal of Medicine* 358, 2765–2775 (2008).
29. Kakkar, A. K. et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *The Lancet* 372, 31–39 (2008).
30. Lassen, M. R. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *New England Journal of Medicine* 358, 2776–2786 (2008).
31. Turpie, A. G. et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. The Lancet 373, 1673–1680 (2009).

32. Turpie, A. G. G. et al. BAY 59–7939: An oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. Journal of Thrombosis and Haemostasis 3, 2479–2486 (2005).

33. Zou, Y., Tian, S., Wang, Y. & Sun, K. Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. Blood Coagulation and Fibrinolysis 25, 660–664 (2014).

34. Dahl, O. E., Quinlan, D. J., Bergqvist, D. & Eikelboom, J. W. A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty. J Thromb Haemost 8, 1966–1975, doi: 10.1111/j.1538-7836.2010.03965.x (2010).

35. Gomez-Outes, A., Suarez-Gea, M. L., Blazquez-Perez, A., Pozo-Hernandez, C. & Vargas-Castrillon, E. Rivaroxaban versus enoxaparin after total knee arthroplasty. Lancet (London, England) 374, 682; author reply 683, doi: 10.1016/s0140-6736(09)61552-x (2009).

36. FDA Cardiovascular & Renal Drugs Advisory Committee. Meeting ID: 2009-4418. www.fda.gov/downloads/advisorycommittees/committeemeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm181524.pdf.

37. Nieto, J. A., Espada, N. G., Merino, R. G. & Gonzalez, T. C. Dabigatran, Rivaroxaban and Apixaban versus Enoxaparin for thromboprophylaxis after total knee or hip arthroplasty: Pool-analysis of phase III randomized clinical trials. Thrombosis Research 130, 183–191 (2012).

38. Turpie, G. G. et al. A pooled Analysis of Four pivotal studies of Rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effect on symptomatic venous thromboembolism and death, and bleeding. Haematologica 94, 212 (2009).

39. Neumann, I. et al. Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med 156, 710–719, doi: 10.7326/0003-4819-156-10-201205150-00421 (2012).

40. Turpie, A. G. et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thrombosis and haemostasis 111, 94–102, doi: 10.1160/ th13-08-0666 (2014).

41. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org.

42. Parvizi, J. et al. Does “excessive” anticoagulation predispose to periprosthetic infection? The Journal of arthroplasty 22, 24–28, doi: 10.1016/j.arthro.2007.03.007 (2007).

43. Russell, R. D. & Huo, M. H. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty: The Journal of arthroplasty 28, 1477–1481, doi: 10.1016/j.arthro.2013.02.016 (2013).

44. Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Bmj 336, 924–926, doi: 10.1136/bmj.3949.470347.AD (2008).

45. Guyatt, G. H. et al. What is “quality of evidence” and why is it important to clinicians? Bmj 336, 995–998, doi: 10.1136/bmj.3949.551019.BE (2008).

46. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Controlled clinical trials 7, 177–188 (1986).

47. Higgins, J. P., Thompson, S. G., Deeks, J. J. & Altman, D. G. Measuring inconsistency in meta-analyses. Bmj 327, 557–560, doi: 10.1136/bmj.327.7414.557 (2003).

48. Altman, D. G. & Bland, J. M. Interaction revisited: the difference between two estimates. Bmj 326, 219 (2003).

49. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analyses detected by a simple, graphical test. Bmj 315, 629–634 (1997).

50. Turner, R. M., Bird, S. M. & Higgins, J. P. The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. Plos One 8, e59202, doi: 10.1371/journal.pone.0059202 (2013).

51. Trikalinos, T. A. et al. Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. Journal of clinical epidemiology 57, 1124–1130 (2004).

52. Brok, J., Thorlund, K., Weterslev, J. & Gluud, C. Apparently conclusive meta-analyses may be inconclusive–Trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International journal of epidemiology 38, 287–298, doi: 10.1093/ije/dyn188 (2009).

53. Weterslev, I., Thorlund, K., Brok, J. & Gluud, C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of clinical epidemiology 61, 64–75, doi: 10.1016/j.jclinepi.2007.03.013 (2008).

54. Holst, L. B., Petersen, M. W., Haase, N., Perner, A. & Weterslev, I. Restrictive versus liberal transfusion strategy for red blood cell transfusion: systematic review of randomised trials with meta-analysis and trial sequential analysis. Bmj 350, h1354, doi: 10.1136/ bmj.h1354 (2015).

55. Schulz, K. F., Chalmers, I., Hayes, R. J. & Altman, D. G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Jama 273, 408–412 (1995).

56. Moher, D. et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet (London, England) 352, 609–613, doi: 10.1016/s0140-6736(98)01085-x (1998).

57. Kaajargard, L. L., Villumsen, J. & Gluud, C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of internal medicine 135, 982–989 (2001).

58. Thorlund, K., Engstrem J., Weterslev J., Brok, J., Imberger G. & Gluud C. User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark. 2011. p.1–115. Available at: www.ctu.dk/tsa.

Acknowledgements
This study was supported by State Key Program of National Natural Science Foundation of China (81330042), Special Program for Sino-Russian Joint Research Sponsored by the Ministry of Science and Technology, China (2014DFB31210) and Key Program Sponsored by the Tianjin Science and Technology Committee, China (13RCGFSY19000, 14ZCZDSY00044).

Author Contributions
G.Z.N., S.Q.F. and Y.Z. conceived and designed the study; G.Z.N., S.L.K. and L.X.C. performed search, reviewed literature and collected the data; G.Z.N., S.L.K. and L.S. performed statistical analyses; G.Z.N. and S.L.K. drafted the manuscript. All authors reviewed the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Ning, G.-Z. et al. Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials. Sci. Rep. 6, 23726; doi: 10.1038/srep23726 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/